EpigenCare - Truly personalized skincare, by combining epigenetics and blockchain technology.

Hi there, crypto and ICO maniac, we are back again with the great news for all of you guys. We glad to explain to you all the first Biotech company for personalized skincare by combining epigenetics and blockchain technology, you can found the great details for your reference here https://ico.epigencare.com. In 2016, global skincare industry revenue was $130 billion USD. By 2023, the industry is expected to grow 5% annually to over $180 billion. By looking at the data above, Epigencare is very observant in seeing the market. As the first biotech company for personalized skincare, epigencare market is predicted to get a lot of spotlight by the wider community. Here is the details what is the epigenCare.

What is epigenCare?

EpigenCare provides personalized skincare data through individual epigenetic analysis of consumers’ DNA samples. Through next-generation sequencing techniques, they will be able to truly identify a consumer’s dynamic skin properties for cogent skincare. Through blockchain technology, epigenCare will be able to maintain anonymity of the consumer while enabling transparency of how their data is being used solely and directly for their own benefit within a structured ecosystem. Subsequently, this allows them to accumulate data to be commoditized (tokenized), leveraged, and commercially used by skincarerelated companies in an intelligent, personalized, and responsible manner.

Problem

As per we all know that the skincare marketplace offers a very large, often confusing, selection of products. Despite many of these products claiming to have scientific substance to mechanisms (e.g., anti-aging, skin brightening, moisture retention, wrinkle firming, etc), consumer buying decisions often depend on non-scientific factors such as flashy advertising, brand loyalty, referrals, social media influencers, and consumer reviews. However, there is always an inherent doubt by the consumer about whether the selected product is working as claimed, fueling a constant search for the ideal product that aligns with his or her skin features.

Solution

EpigenCare very care about the above problem. They aim to facilitate a major shift in the buying decision process – from a push method of the skincare product manufacturer/retailer to a pull method by the consumer. A two-part solution is proposed accordingly:

First, epigenCare will offer a personalized skincare test to the consumer that will test for the epigenetic profile of one’s skin
Second, epigenCare will commoditize the accumulated data from the tests and build a supply-and-demand modeled data platform (the “EpigenCare Network”) for skincare product manufacturers and/or retailers to purchase data points from.

Benefit To Investing EPIC Token

As per I said before that the global skincare market is grow up every years. In 2016, global skincare industry revenue was $130 billion USD. By 2023, the industry is expected to grow 5% annually to over $180 billion.1 The market value is mainly distributed in the following regions accordingly:

According to a 2017 US survey, around 147 million US residents regularly purchased skincare products, 30 million of whom spent between $100 to $500 per person within 3 months (or $400 to $2,000 annually), with a further 1.4 million consumers spending more than $2,000 annually. To calculate the estimated number of regular skincare product users globally, we need to account for purchasing power parity and thus we looked at the lowest spending tier in the US – 75 million US residents spent less than $50 within 3 months (or less than $200 annually). If we take a median spend of $100 per person annually and apply it on a global basis, and since the global market value for skincare products is over $130 billion, then we can estimate that a total of at least 1 billion people regularly purchases skincare products. By looking that data can deduced that in future demand for epigenCare token will grow and will affect also with their value.

you can see below for epigenCare structured ecosystem perpetuates cyclical growth.

EpigenCare are one of the only ICO biotechnology companies that do not have to go through long and cumbersome FDA clinical trials or regulatory approval. Epigencare will be able to quickly deploy a commercialized skincare test into the market for immediate consumer use.

EPIC tokens are a direct investment into the valuable, core business mechanism of the company. EpigenCare are raising capital via an Initial Coin Offering as a concurrent Regulation D 506(c) and Regulation S, filed with the US Securities & Exchange Commission. EPIC investors will receive dividend payouts in the form of ETH, equivalent to 15%, 10%, and 5% of the first three years' worth of sales revenue, respectively. As a US-incorporated company with SEC compliant tokens, they offer a realistic opportunity for investors to make the ideal investment towards significant, sustained long-term growth and liquidity.

EpigenCare vision is to build a high value, high revenue-generating business.

In an age of Googles and Ubers, we're creating an entirely new business sector by commoditizing skincare data. We intend to be the first ICO'd company to achieve mainstream consumer adoption with real revenue growth.

Token Sale Specsifications

epigenCare Team

WILLIAM LEE

Chief Executive Officer

William Lee is an entrepreneur with over 10 years of experience in both the biotechnology and entertainment sectors. He is currently a shareholder and senior executive of EpiGentek Group Inc., a biotechnology reagents company specializing in epigenetics, and had also previously founded music licensing and gaming ventures. He has significant experience in management, operations, web development, and both B2B and B2C marketing. Having a passion for disruptive technologies, he invested in Bitcoin in 2013 and subsequently Ethereum in its early days. William Lee studied at New York University and Carnegie Mellon University. While pursuing his MBA at the Carnegie Mellon Tepper School of Business, William realized the vast startup opportunity in the blockchain space and sought to bring the disruptive technology into consumer biotech.

ADAM WEIWEI LI, MD, PH.D.

Chief Scientific Officer

Dr. Adam Li is the scientific founder and CSO of EpiGentek Group, Inc. with more than 20 years of experience in oncology and pharmacology as well as 15 years of experience in epigenetic research. His publication list includes 46 peer-reviewed papers in the cancer and epigenetic fields. As the first inventor, he has filed 11 patent applications related to epigenetic test methods and medical cosmetics, in which 4 patents were issued. Dr. Li completed his postdoctoral training at Memorial Sloan-Kettering Cancer Center and served as faculty-level attending biologist at Memorial Hospital in New York prior to joining EpiGentek. He was also the visiting professor at University of South China Medical College and a reviewer of several top biological journals including Cancer Research and Nucleic Acid Research.

JESSICA LI

Chief Financial Officer

Jessica has more than 20 years of experience in accounting, finance, banking, and business management. She is a co-founder and the CFO of EpiGentek Group, Inc. where she developed and facilitated financial strategies, budget and cost management, and accounting operations to ultimately increase overall enterprise value. Before joining EpiGentek, she worked at several CPA firms as well as in the banking sector in New York. She holds a bachelor’s degree in finance and an MBA from the New York Institute of Technology School of Management with a concentration in accounting.

ASHLEY POTTASH

Business Strategy Lead

Ashley Pottash is a strategic and creative brand builder with more than 8 years’ experience in the fashion and beauty industries. She specializes in visual merchandising for luxury brands and is Senior Manager of Global Visual Merchandising at Coty, Inc. for Marc Jacobs and Calvin Klein fragrances. Ashley served as Manager of Merchandise Development and Purchasing at CHANEL for all makeup, skincare, and fragrance point of sale collateral. After leaving CHANEL, she spearheaded visual merchandising and store design for the innovative beauty and skincare brand, Charlotte Tilbury. Ashley graduated early from the Robins School of Business at the University of Richmond with a focus on business and marketing.

STEPHEN FISER

Software Development Lead

Stephen Fiser is a software engineer specializing in blockchain technology, Solidity, and dApps. After graduating from the University of Arkansas with a degree in biophysics, Stephen worked in the corporate information technology sector. Wanting to focus on emerging technologies, he moved to New York City and shifted gears to work with startup companies until 2014 when he founded Blue Bear Digital Inc., a full-fledged software development agency.